Abstract:Abstract Background RSVPreF3 OA was recently approved by the United States FDA for the prevention of RSV-related lower respiratory tract disease (RSV-LRTD) in adults ≥ 60 years of age (YOA). We present persistence of vaccine efficacy (VE) of a single RSVPreF3 OA dose, along with VE and safety of annual revaccination dose, over 2 RSV seasons. Methods In this phase 3, placebo-controlled, multi-country study (NCT04886596), adults ≥ 60 YOA were randomized 1:1 to receive RSVPreF3 OA or placebo before RSV season 1. RSVPreF3 OA recipients were then re-randomized 1:1 before RSV season 2 to receive a second RSVPreF3 OA dose (RSV_annual group) or placebo (RSV_1dose group); participants who received placebo pre-season 1 received an additional placebo dose (placebo group). VE against first occurrence of RSV-LRTD (confirmatory secondary objectives), severe RSV-LRTD, RSV-LRTD by age, baseline comorbidity and frailty status, and RSV-related acute respiratory illness (ARI) was assessed over 2 seasons. Reactogenicity and safety were also evaluated. Results Of 24,973 participants vaccinated before season 1, 24,967 were included in the current VE analyses (RSV_annual: 6,242; RSV_1dose: 6,227; placebo: 12,498). The median follow-up over 2 seasons was 17.8 months. VE of a single dose of RSVPreF3 OA against RSV-LRTD over 2 seasons was 67.2% (97.5% confidence interval [CI]: 48.2–80.0); VE of annual revaccination over 2 seasons was 67.1% (97.5% CI: 48.1–80.0). Sustained VE was observed over 2 seasons against severe RSV-LRTD, against RSV-LRTD among participants 60–69 YOA, 70–79 YOA, those with ≥ 1 baseline comorbidity of interest, pre-frail participants and against RSV-ARI (Figure 1). The reactogenicity (Figure 2) and safety profile of the second RSVPreF3 OA dose was in line with the first dose. Conclusion One dose of RSVPreF3 OA is efficacious against RSV-LRTD in adults ≥ 60 YOA over 2 full RSV seasons, as well as against severe RSV-LRTD, and in adults with advanced ages and underlying comorbidities. Revaccination after 1 year does not appear to confer additional efficacy benefit for the overall population. The second RSVPreF3 OA dose had a clinically acceptable safety profile. The clinical development program will further evaluate persistence and the best timing for revaccination. Funding: GlaxoSmithKline Biologicals SA Disclosures Michael G. Ison, MD MS, Adagio: Advisor/Consultant|Adamis: Advisor/Consultant|Adamis: Board Member|ADMA Biologics: Advisor/Consultant|AlloVir: Advisor/Consultant|AlloVir: Board Member|Atea: Advisor/Consultant|Cidara: Advisor/Consultant|CSL Behring: Board Member|Genentech/Roche: Advisor/Consultant|GSK: Grant/Research Support|Janssen: Advisor/Consultant|Janssen: Board Member|Merck: Board Member|NIH: Board Member|Romark: Advisor/Consultant|Seqiris: Board Member|Shionogi: Advisor/Consultant|Takeda: Advisor/Consultant|Takeda: Board Member|Talaris: Advisor/Consultant|Talaris: Board Member|UpToDate: Stocks/Bonds|Viracor Eurofins: Advisor/Consultant Alberto Papi, MD, Agenzia Italiana del farmaco (AIFA): Grant/Research Support|AstraZeneca: Advisor/Consultant|AstraZeneca: Board Member|AstraZeneca: Grant/Research Support|AstraZeneca: Honoraria|Avillon: Advisor/Consultant|Avillon: Honoraria|Chiesi Farmaceutici: Advisor/Consultant|Chiesi Farmaceutici: Board Member|Chiesi Farmaceutici: Grant/Research Support|Chiesi Farmaceutici: Honoraria|EdmondPharma: Honoraria|Elpen Pharmaceuticals: Advisor/Consultant|Elpen Pharmaceuticals: Honoraria|GSK: Advisor/Consultant|GSK: Board Member|GSK: Grant/Research Support|MENARINI: Honoraria|Mundipharma: Honoraria|Novartis: Advisor/Consultant|Novartis: Honoraria|Qivia: Honoraria|Sanofi: Advisor/Consultant|Sanofi: Board Member|Sanofi: Grant/Research Support|Sanofi: Honoraria|Zambon: Honoraria Joanne M. Langley, MD, GSK: Grant/Research Support|Inventprise: Grant/Research Support|Merck: Grant/Research Support|Moderna: Grant/Research Support|Pfizer: Grant/Research Support|Sanofi: Grant/Research Support|Seqirus: Board Member|Vaxcyte: Data Safety review board|VBI: Grant/Research Support Isabel Leroux-Roels, PhD MD, Curevac: Grant/Research Support|GSK: Board Member|GSK: Grant/Research Support|ICON Genetics: Grant/Research Support|ICON Genetics: Yes|Icosavax: Grant/Research Support|Janssen Vaccines: Advisor/Consultant|Janssen Vaccines: Board Member|Janssen Vaccines: Grant/Research Support|Moderna: Grant/Research Support|MSD: Advisor/Consultant|MSD: Grant/Research Support|OSE Immunotherapeutics: Grant/Research Support|Osivax: Grant/Research Support|Virometrix: Grant/Research Support Federico Martinon-Torres, MD, PhD, Assoc. Prof, Abbot: Principal Investigator in randomized controlled trials|Ablynx: Principal Investigator in randomized controlled trials|AstraZeneca: Advisor/Consultant|AstraZeneca: Grant/Research Support|AstraZeneca: Honoraria|Biofabri: Advisor/Consultant|Biofabri: Board Member|Biofabri: Grant/Research Support|Biofabri: Honoraria|GSK: Advisor/Consultant|GSK: Grant/Research Support|GSK: Honoraria|GSK: Clínical trials fees paid to my institution|Janssen: Advisor/Consultant|Janssen: Grant/Research Support|Janssen: Honoraria|Janssen: Clínical trials fees paid to my institution|Medimmune: Principal Investigator in randomized controlled trials|Merck: Grant/Research Support|Moderna: Advisor/Consultant|Moderna: Grant/Research Support|Moderna: Honoraria|MSD: Advisor/Consultant|MSD: attending meetings and/or travel, Principal Investigator in randomized controlled trials|Novartis: Principal Investigator in randomized controlled trials|Novavax: Honoraria|Pfizer: Advisor/Consultant|Pfizer: Board Member|Pfizer: Grant/Research Support|Pfizer: Honoraria|Pfizer: Clínical trials fees paid to my institution|Regeneron: Principal Investigator in randomized controlled trials|Roche: Principal Investigator in randomized controlled trials|Sanofi: Advisor/Consultant|Sanofi: Grant/Research Support|Sanofi: Honoraria|Sanofi: Clínical trials fees paid to my institution|Seqirus: Principal Investigator in randomized controlled trials Tino F. Schwarz, Prof. Dr. MD, Alexion: Honoraria|AstraZeneca: Honoraria|Bavarian Nordic: Advisor/Consultant|Bavarian Nordic: Honoraria|Biogen: Honoraria|BioNTech: Board Member|BioNTech: Honoraria|GSK: Advisor/Consultant|GSK: Honoraria|Janssen-Cilag: Advisor/Consultant|Janssen-Cilag: Honoraria|Merck-Serono: Advisor/Consultant|Merck-Serono: Honoraria|Moderna: Advisor/Consultant|Moderna: Honoraria|MSD: Honoraria|Novavax: Advisor/Consultant|Novavax: Honoraria|Pfizer: Honoraria|Roche: Honoraria|Sanofi-Aventis: Honoraria|Seqirus: Advisor/Consultant|Seqirus: Honoraria|Synlab: Honoraria|Takeda: Advisor/Consultant|Takeda: Honoraria|va-Q-tec: Honoraria Richard N. Van Zyl-Smit, PhD MD, Boehringer Ingelheim: Grant/Research Support|Boehringer Ingelheim: Honoraria|CIPLA: Honoraria|Glenmark: Honoraria|GSK: Advisor/Consultant|Novartis: Honoraria|OnQsa: Advisor/Consultant Susanna Cuadripani, MD, GSK: GSK Employee Nancy Dezutter, PhD, PharmD, GSK: Patents still under assessment|GSK: GSK Employee|GSK: Stocks/Bonds|Haleon: Stocks/Bonds Olivier Gruselle, MS, GSK: GSK Employee|GSK: Stocks/Bonds Laurence Fissette, Master in Statistics, GSK: RSV vaccine patent|GSK: GSK Employee|GSK: Stocks/Bonds Marie-Pierre David, Master in Statistics, GSK: GSK Employee|GSK: Stocks/Bonds Aurélie Olivier, PhD, GSK: Yes|GSK: GSK Employee|GSK: Stocks/Bonds Marie Van Der Wielen, MD, GSK: GSK Employee|GSK: Stocks/Bonds Dominique Descamps, MD, GSK: GSK Employee|GSK: Stocks/Bonds

1936. Efficacy of One Dose of the Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Adults ≥ 60 Years of Age Persists for 2 RSV Seasons

LB745. Respiratory Syncytial Virus (RSV) Prefusion F Protein Candidate Vaccine (RSVPreF3 OA) is Efficacious in Adults ≥ 60 Years of Age (YOA)

121. A Respiratory Syncytial Virus Prefusion F Protein (RSVPreF3) Candidate Vaccine Administered in Older Adults in a Phase I/II Randomized Clinical Trial Is Immunogenic

96. A Candidate Respiratory Syncytial Virus (RSV) Prefusion F Protein Investigational Vaccine (RSVPreF3 OA) Is Immunogenic when Administered in Adults ≥ 60 Years of Age: Results at 6 Months after Vaccination

119. Safety and Reactogenicity of an Investigational Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine for Adults ≥ 60 Years of Age (RSVPreF3 OA): an Interim Analysis at 6 Months after Vaccination

Efficacy and safety of respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons

2321. Long-term immunogenicity of Ad26.RSV.preF/RSV preF protein vaccine against RSV in a phase 2b study by age and risk level

1634. Respiratory Syncytial Virus-Associated Health Care Utilization in the Pivotal Phase 3 Trial RSV Vaccine Efficacy Study In Older Adults Immunized Against RSV Disease (RENOIR)

280-LB: Efficacy of a Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults with Preexisting Medical Conditions

LB748. Efficacy And Safety Of Bivalent Respiratory Syncytial Virus (RSVpreF) Vaccine In Older Adults

LB13. The Efficacy and Impact in Heathy Infants of Nirsevimab on Medically Attended RSV Lower Respiratory Tract Infection

LB14. Efficacy and Immunogenicity of an Ad26.RSV.preF-based Vaccine in the Prevention of RT-PCR-confirmed RSV-mediated Lower Respiratory Tract Disease in Adults Aged ≥65 Years: A Randomized, Placebo-controlled, Phase 2b Study

1934. Nirsevimab is Associated with Higher and More Sustained RSV Neutralizing Antibody Responses Compared with Standard of Care Palivizumab: Observations from a 2:1 Randomized, Phase 2/3 Trial in Medically Vulnerable Children (MEDLEY)

1630. Clinical Profile of Acute Respiratory Illness (ARI) Events in the Phase 3 Trial The RSV Vaccine Efficacy Study iN Older Adults Immunized against RSV Disease (RENOIR)

Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions

2641. Nirsevimab binding-site conservation in RSV F protein between 2015 and 2022: The US OUTSMART-RSV surveillance study

Immunogenicity, safety and reactogenicity of Ad26.RSV.preF/RSV preF protein vaccine in adults aged 60 to 75 years: A comparison of phase 2b and phase 3 clinical trial material

1013. Predicting RSV Efficacy for MK-1654 in Temperate and Tropical Climates using MBMA and Clinical Trial Simulation to Account for Seasonal Differences in RSV Force-of-Infection

LB747. Immune Responses of the Recombinant MVA-BN-RSV Vaccine against Respiratory Syncytial Virus Infection in an RSV Human Challenge Trial (HCT) in Healthy Adult Participants

Long-term efficacy and immunogenicity of Ad26.RSV.preF–RSV preF protein vaccine (CYPRESS): a randomised, double-blind, placebo-controlled, phase 2b study

2655. Phase 1 Safety and Immunogenicity Results of Two Investigational mRNA Vaccines, mRNA-1345, a Respiratory Syncytial Virus Vaccine, and mRNA-1653, a Human Metapneumovirus and Parainfluenza Virus Type 3 Combination Vaccine in Seropositive Young Children